Strides Pharma Reports Profit Surge Amid Global Growth

Strides Pharma Science Ltd reported a consolidated net profit rise of 51% to Rs 129.28 crore for Q4 ending March 31, 2026. Strong growth in markets outside the US contributed, with revenue rising to Rs 1,323.47 crore. The company maintains focus on profitability amidst global challenges.

Strides Pharma Science Ltd announced a significant 51% increase in its consolidated net profit for the fourth quarter, reaching Rs 129.28 crore, compared to the same period last year, largely due to robust growth in its non-US markets.

The company's revenue from operations for the quarter grew to Rs 1,323.47 crore, up from Rs 1,190.39 crore the previous year. Excluding the US, market revenue soared to Rs 645.8 crore, evidencing the effectiveness of Strides Pharma's targeted strategy, according to a regulatory filing.

Despite a stable but slightly weakened performance in the US market attributed to a weaker flu season, the company's MD & Group CEO, Badree Komandur, emphasized confidence in maintaining sustainable growth amidst global uncertainties. A final dividend of Rs 5 per share has been recommended for the fiscal year.